LT3981414T - Didelio paviršiaus ploto liofilizuotos kompozicijos, apimančios arseną, skirtos pacientams įvedant peroraliniu būdu - Google Patents

Didelio paviršiaus ploto liofilizuotos kompozicijos, apimančios arseną, skirtos pacientams įvedant peroraliniu būdu

Info

Publication number
LT3981414T
LT3981414T LTEP21192594.6T LT21192594T LT3981414T LT 3981414 T LT3981414 T LT 3981414T LT 21192594 T LT21192594 T LT 21192594T LT 3981414 T LT3981414 T LT 3981414T
Authority
LT
Lithuania
Prior art keywords
patients
surface area
oral administration
compositions containing
large surface
Prior art date
Application number
LTEP21192594.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Krishna Vaddi
Kumar KURUMADDALI
Original Assignee
Quetzal Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quetzal Therapeutics, Llc filed Critical Quetzal Therapeutics, Llc
Publication of LT3981414T publication Critical patent/LT3981414T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP21192594.6T 2015-02-01 2016-02-01 Didelio paviršiaus ploto liofilizuotos kompozicijos, apimančios arseną, skirtos pacientams įvedant peroraliniu būdu LT3981414T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562110574P 2015-02-01 2015-02-01
US201562142709P 2015-04-03 2015-04-03

Publications (1)

Publication Number Publication Date
LT3981414T true LT3981414T (lt) 2025-09-25

Family

ID=56544541

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP21192594.6T LT3981414T (lt) 2015-02-01 2016-02-01 Didelio paviršiaus ploto liofilizuotos kompozicijos, apimančios arseną, skirtos pacientams įvedant peroraliniu būdu

Country Status (20)

Country Link
US (6) US10111836B2 (enExample)
EP (3) EP3981414B1 (enExample)
JP (3) JP6928768B2 (enExample)
CN (2) CN107530373B (enExample)
AU (4) AU2016211186A1 (enExample)
CA (2) CA2975406C (enExample)
DK (1) DK3981414T3 (enExample)
ES (2) ES3034734T3 (enExample)
FI (1) FI3981414T3 (enExample)
HR (1) HRP20251032T1 (enExample)
HU (1) HUE072537T2 (enExample)
LT (1) LT3981414T (enExample)
MX (2) MX390835B (enExample)
PL (1) PL3981414T3 (enExample)
PT (1) PT3981414T (enExample)
RS (1) RS67133B1 (enExample)
SI (1) SI3981414T1 (enExample)
SM (1) SMT202500321T1 (enExample)
TW (3) TWI790191B (enExample)
WO (1) WO2016123603A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975406C (en) 2015-02-01 2025-07-22 Quetzal Therapeutics, Llc LYOPHILIZED COMPOSITIONS WITH HIGH SPECIFIC SURFACE AREA CONTAINING ARSENIC INTENDED FOR ORAL ADMINISTRATION IN PATIENTS
US20260027056A1 (en) * 2015-02-01 2026-01-29 Quetzal Therapeutics, Llc High surface-area lyophilized compositions comprising arsenic for oral administration in patients
AU2017368444B9 (en) 2016-12-01 2020-07-02 Eupharma Pty Ltd Arsenic compositions
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
US20190374611A1 (en) * 2017-01-18 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US12582984B1 (en) 2020-07-02 2026-03-24 Argonaut Manufacturing Services, Inc. Method for lyophilization and device thereof
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
JP7428842B1 (ja) 2023-03-29 2024-02-06 artience株式会社 活性エネルギー線硬化型インキ、その製造方法、および印刷物
AU2025223378A1 (en) * 2024-02-14 2026-07-30 Assistance Publique - Hôpitaux De Paris Oral composition of arsenic trioxide for cancer treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773419A (en) 1995-03-03 1998-06-30 Falcon; Juan Method of treating cancer with tannic acid
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US7276359B1 (en) * 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
CN1131922C (zh) 1998-10-19 2003-12-24 张在喆 一种通过弹性键搭架与收拢的帐篷
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CN102772413A (zh) * 2000-02-29 2012-11-14 布里斯托尔-迈尔斯斯奎布公司 低剂量艾替开韦制剂及其应用
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
US8906422B2 (en) 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
CN1251688C (zh) 2003-12-09 2006-04-19 重庆维特瑞医药开发有限公司 三氧化二砷冻干粉针及其生产方法
JP4292985B2 (ja) 2003-12-25 2009-07-08 Jsr株式会社 感放射線性組成物、マイクロレンズとその形成方法および液晶表示素子
CN1698650A (zh) 2004-05-21 2005-11-23 哈尔滨伊达药业有限公司 一种治疗原发性肝癌的亚砷酸注射液及其制备方法
CN1326528C (zh) 2004-07-13 2007-07-18 东南大学 砒霜磁性纳米明胶微球的制备工艺
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
CN101322719B (zh) 2007-06-15 2012-03-07 杭州民生药业有限公司 一种三氧化二砷固体脂质纳米粒及其制剂
US8168224B2 (en) * 2007-12-19 2012-05-01 Beijing Shengyiyao Science & Technology Development Co., Ltd. Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof
US20110165259A1 (en) 2008-09-19 2011-07-07 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
EP2525783A1 (en) 2010-01-18 2012-11-28 Cephalon France Improved oral lysophilisates containing pvp/va
CN103142648B (zh) 2011-12-07 2015-04-15 浙江中医药大学 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂
CN103408477B (zh) 2013-08-22 2015-06-10 陈鹏飞 一种含砷配位化合物及其制备方法
PL3250213T3 (pl) 2015-01-29 2023-10-30 Eupharma Pty Ltd Kompozycje zawierające arsen do stosowania w sposobach leczenia
CA2975406C (en) 2015-02-01 2025-07-22 Quetzal Therapeutics, Llc LYOPHILIZED COMPOSITIONS WITH HIGH SPECIFIC SURFACE AREA CONTAINING ARSENIC INTENDED FOR ORAL ADMINISTRATION IN PATIENTS

Also Published As

Publication number Publication date
CA2975406C (en) 2025-07-22
SMT202500321T1 (it) 2025-11-10
EP3250214B1 (en) 2021-09-01
EP3981414B1 (en) 2025-06-25
US20230310325A1 (en) 2023-10-05
HUE072537T2 (hu) 2025-11-28
JP6928768B2 (ja) 2021-09-01
NZ772450A (en) 2024-07-05
US12364664B2 (en) 2025-07-22
JP2021152059A (ja) 2021-09-30
MX390835B (es) 2025-03-21
US20200060974A1 (en) 2020-02-27
JP2018503696A (ja) 2018-02-08
US20160235679A1 (en) 2016-08-18
TW202337477A (zh) 2023-10-01
EP3250214A4 (en) 2018-09-19
AU2016211186A1 (en) 2017-08-17
US10111836B2 (en) 2018-10-30
CA2975406A1 (en) 2016-08-04
FI3981414T3 (fi) 2025-07-29
HK1248113A1 (zh) 2018-10-12
PL3981414T3 (pl) 2025-10-06
JP7539855B2 (ja) 2024-08-26
MX2017009913A (es) 2018-08-15
US10272045B2 (en) 2019-04-30
CN117899029A (zh) 2024-04-19
AU2025259861A1 (en) 2025-11-20
JP7885288B2 (ja) 2026-07-06
AU2021203752A1 (en) 2021-07-08
MX2020012611A (es) 2021-02-09
AU2023214307B2 (en) 2025-08-21
CN107530373B (zh) 2023-12-29
ES3034734T3 (en) 2025-08-22
TWI790191B (zh) 2023-01-21
AU2023214307A1 (en) 2023-08-31
ES2899226T3 (es) 2022-03-10
TW201642879A (zh) 2016-12-16
WO2016123603A2 (en) 2016-08-04
US20190029963A1 (en) 2019-01-31
EP3250214A2 (en) 2017-12-06
US10653628B2 (en) 2020-05-19
JP2024161468A (ja) 2024-11-19
CN107530373A (zh) 2018-01-02
CA3225480A1 (en) 2016-08-04
DK3981414T3 (da) 2025-07-14
WO2016123603A3 (en) 2016-11-03
PT3981414T (pt) 2025-07-22
TW202228734A (zh) 2022-08-01
SI3981414T1 (sl) 2025-10-30
HRP20251032T1 (hr) 2025-10-24
EP4599823A1 (en) 2025-08-13
RS67133B1 (sr) 2025-09-30
US20210069115A1 (en) 2021-03-11
NZ734201A (en) 2024-03-22
EP3981414A1 (en) 2022-04-13
AU2021203752B2 (en) 2023-08-31
US20240269076A1 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
IL257531A (en) Therapeutic combinations comprising anti-folr1 immunoconjugates
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
EP4233846C0 (en) PHARMACEUTICAL FORMULATIONS
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
EP4169508B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ALPELISAB
IL259044B (en) compounds for oral care
DK3981414T3 (da) Lyofiliserede præparater med højt overfladeareal, der indeholder arsenik til oral indgivelse i patienter
ZA201803909B (en) Oral care compositions
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
ZA201706785B (en) Oral care compositions
PT3157506T (pt) Composição farmacêutica oral com sabor mascarado
SI3318259T1 (sl) Stabilni farmacevtski sestavki za oralno dajanje
DK3280447T3 (da) Farmaceutiske formuleringer
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
ZA201604100B (en) Gastro-retentive oral pharmaceutical compositions
DK3107568T3 (da) Formuleringer til indgivelse til tyndtarmen
SG11201708597VA (en) Oral care composition
ZA201801038B (en) Oral care compositions
ZA201800096B (en) Oral care compositions
KR20180084728A (ko) 구강용 조성물
DK2952207T3 (da) Oliebaserede farmaceutiske sammensætninger til oral indgivelse
LT3377044T (lt) Ibuprofeno kompozicijos, skirtos tiesioginiam peroraliniam įvedimui
ZA201801992B (en) Oral care compositions
BR112017004882A2 (pt) composição farmacêutica oral.
CO6990731A2 (es) Composiciones de cuidado oral